Hutchison china meditech ltd - adr HCM.US 總覽分析
HCM 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
HCM 近期報酬表現
-2.27%
Hutchison china meditech ltd - adr
0.38%
同產業平均
-0.07%
S&P500
與 HCM 同產業的標的表現
- ONC Beigene, ltd. - adr價值 3 分趨勢 2 分波段 2 分籌碼 2 分股利 1 分查看更多
HCM 公司資訊
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.